Drugs in primary care that may alter COVID-19 risk and severity
Copyright © 2023 American Academy of Physician Associates..
ABSTRACT: This article describes drugs used in primary care that could alter patients' risk for and severity of COVID-19. The risks and benefits of each drug class were differentiated according to the strength of evidence from 58 selected randomized controlled trials, systematic reviews, and meta-analyses. Most of the studies reported on drugs affecting the renin-angiotensin-aldosterone system. Other classes included opioids, acid suppressants, nonsteroidal anti-inflammatory drugs, corticosteroids, vitamins, biguanides, and statins. Current evidence has not fully differentiated drugs that may increase risk versus benefits in COVID-19 infection. Further studies are needed in this area.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
JAAPA : official journal of the American Academy of Physician Assistants - 36(2023), 5 vom: 01. Mai, Seite 28-33 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Luu, Brent [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Adrenal Cortex Hormones |
|---|
| Anmerkungen: |
Date Completed 27.04.2023 Date Revised 17.08.2023 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1097/01.JAA.0000918768.11544.e5 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM356014355 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM356014355 | ||
| 003 | DE-627 | ||
| 005 | 20231226065548.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1097/01.JAA.0000918768.11544.e5 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1186.xml |
| 035 | |a (DE-627)NLM356014355 | ||
| 035 | |a (NLM)37097779 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Luu, Brent |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drugs in primary care that may alter COVID-19 risk and severity |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.04.2023 | ||
| 500 | |a Date Revised 17.08.2023 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 American Academy of Physician Associates. | ||
| 520 | |a ABSTRACT: This article describes drugs used in primary care that could alter patients' risk for and severity of COVID-19. The risks and benefits of each drug class were differentiated according to the strength of evidence from 58 selected randomized controlled trials, systematic reviews, and meta-analyses. Most of the studies reported on drugs affecting the renin-angiotensin-aldosterone system. Other classes included opioids, acid suppressants, nonsteroidal anti-inflammatory drugs, corticosteroids, vitamins, biguanides, and statins. Current evidence has not fully differentiated drugs that may increase risk versus benefits in COVID-19 infection. Further studies are needed in this area | ||
| 650 | 4 | |a Journal Article | |
| 650 | 7 | |a Adrenal Cortex Hormones |2 NLM | |
| 650 | 7 | |a Anti-Inflammatory Agents, Non-Steroidal |2 NLM | |
| 700 | 1 | |a Wijesinghe, Sampath |e verfasserin |4 aut | |
| 700 | 1 | |a Kassem, Tarek |e verfasserin |4 aut | |
| 700 | 1 | |a Lien, Justin |e verfasserin |4 aut | |
| 700 | 1 | |a Luu, Darrick |e verfasserin |4 aut | |
| 700 | 1 | |a Wijesinghe, Rynee |e verfasserin |4 aut | |
| 700 | 1 | |a Luu, Leianna |e verfasserin |4 aut | |
| 700 | 1 | |a Kayingo, Gerald |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t JAAPA : official journal of the American Academy of Physician Assistants |d 1998 |g 36(2023), 5 vom: 01. Mai, Seite 28-33 |w (DE-627)NLM094547211 |x 1547-1896 |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2023 |g number:5 |g day:01 |g month:05 |g pages:28-33 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1097/01.JAA.0000918768.11544.e5 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2023 |e 5 |b 01 |c 05 |h 28-33 | ||